SCHEMBL3303652

SCHEMBL3303652

CCOC(=O)Cc1c(C)c(Sc2ccc(-c3ccccn3)cc2)n2cc(F)ccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.40
HPGD P15428 2/20 0.38
HTT P42858 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
POLB P06746 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CYP1A2 P05177 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP3A4 P08684 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 2/20 0.35
L3MBTL1 Q9Y468 4/20 0.35
TSHR P16473 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3303664 0.89 PTGDR2 (0.51) PTGDR2ALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL3306777 0.84 PTGDR2 (0.40) PTGDR2HPGDHTTALDH1A1KDM4E
SCHEMBL3303384 0.83 PTGDR2 (0.40) PTGDR2HPGDALDH1A1KDM4EHSD17B10
SCHEMBL3302540 0.83 PTGDR2 (0.42) PTGDR2HPGDALDH1A1KDM4EHSD17B10
SCHEMBL3304453 0.82 PTGDR2 (0.46) PTGDR2HPGDALDH1A1MEN1KMT2A
SCHEMBL3302504 0.81 PTGDR2 (0.41) PTGDR2KDM4EMEN1KMT2ACYP1A2
SCHEMBL3569716 0.81 PTGDR2 (0.45) PTGDR2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL3302617 0.81 PTGDR2 (0.40) PTGDR2HPGDMEN1KMT2APOLB
SCHEMBL2774269 0.78 PTGDR2 (0.51) PTGDR2HTTALDH1A1KDM4EHSD17B10
SCHEMBL2771246 0.78 PTGDR2 (0.46) PTGDR2HPGDHTTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093751-A1 Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor ARGENTA DISCOVERY LIMITED (GB) 2010-04-15 US disclosed
EP-2121686-A1 INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR Argenta Discovery Limited (GB) 2009-11-25 EP disclosed
WO-2008078069-A1 INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR ARGENTA DISCOVERY LIMITED (GB) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093751-A1 Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor HRH2, HRH4, HRH1 PTGDR2 168/4885HPGD 1077/4885HTT 3599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.